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background:  A recent trial showed increased major bleeding with no efficacy difference between pretreatment with prasugrel versus prasugrel use 
during PCI in NSTEMI patients. Outcomes associated with thienopyridine pretreatment vs use during PCI were evaluated in MI pts undergoing PCI in 
routine practice.
methods: In 9,251 thienopyridine naïve MI pts undergoing PCI in the TRANSLATE-ACS study, risks of in-hospital major adverse cardiovascular 
events (MACE, defined as death, MI, stroke, or unplanned revascularization) and major bleeding were compared between pts with and without pre-
treatment (prior to PCI) using inverse probability weighted propensity adjustment.
results: Pretreatment use was greater in clopidogrel-treated pts (3,577/6,826[52.4%]) than in prasugrel-treated pts (479/2,425 [19.8%]; p 
<0.0001). Pretreatment was only slightly higher in STEMI pts compared with NSTEMI pts (clopidogrel 54% vs 51%; prasugrel 22% vs 16%). Observed 
and adjusted outcomes showed no difference in MACE by timing of treatment in either clopidogrel or prasugrel pts. Additionally, no differences in 
major bleeding were seen in either prasugrel or clopidogrel pts (Table). When these results were stratified by MI type, again, no differences in MACE 
or bleeding were noted comparing timing of treatment.
Conclusion: In an observational study of routine practice, pretreatment with a P2Y12 inhibitor compared with use in the cath lab was associated 
with similar in-hospital MACE and bleeding risks after adjustment.
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